Edition:
United Kingdom

People: Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

37.35USD
13 Nov 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$37.35
Open
$37.40
Day's High
$38.31
Day's Low
$35.90
Volume
1,080,864
Avg. Vol
789,727
52-wk High
$111.36
52-wk Low
$33.52

Robin, Howard 

Mr. Howard W. Robin is President, Chief Executive Officer, Director of the Company. Mr. Robin served as Chief Executive Officer, President and a director of Sirna Therapeutics, Inc., a biotechnology company, from July 2001 to November 2006 and from January 2001 to June 2001, served as their Chief Operating Officer, President and as a director. From 1991 to 2001, Mr. Robin was Corporate Vice President and General Manager at Berlex Laboratories, Inc. (“Berlex”), a pharmaceutical products company that is a subsidiary of Schering, AG, and from 1987 to 1991 he served as Vice President of Finance and Business Development and Chief Financial Officer. From 1984 to 1987, Mr. Robin was Director of Business Planning and Development at Berlex. He was a Senior Associate with Arthur Andersen & Co. prior to joining Berlex. He received his B.S. in Accounting and Finance from Fairleigh Dickinson University and serves as a member of its Board of Trustees.

Basic Compensation

Total Annual Compensation, USD 2,539,890
Restricted Stock Award, USD 6,884,890
Long-Term Incentive Plans, USD --
All Other, USD 8,672,630
Fiscal Year Total, USD 18,097,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 591,667 8,703,750.00
Name Fiscal Year Total

Robert Chess

556,763

Howard Robin

18,097,400

Gilbert Labrucherie

7,780,090

John Nicholson

7,831,160

Jillian Thomsen

--

Stephen Doberstein

7,698,950
As Of  31 Dec 2017